April Nedeau, MD
Vascular Surgery · Ogden, UTNPI 1497802185
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 77.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $8,400 and has fallen 98.9% since, to $89 in 2025.
Across 48 payments — averaging $194.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Silk Road Medical, Inc.$1K
- Endologix LLC$420
- Biomerieux Inc$162
- Medtronic$139
- W. L. Gore & Associates, Inc.$107
- plus $184 from 7 others
Across 1 payment — averaging $1198.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$1K
What the payments were for
- Consulting fees$2,41226%
- Speaking & faculty fees$3,35636%
- Travel & lodging$2,16023%
- Food & beverage$1,34414%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $7,215 |
| Silk Road Medical, Inc. | 8 | $1,093 |
| Endologix LLC | 4 | $420 |
| Biomerieux Inc | 1 | $162 |
| Medtronic | 7 | $139 |
| W. L. Gore & Associates, Inc. | 3 | $107 |
| Boston Scientific | 3 | $55 |
| Johnson & Johnson | 1 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Novartis | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,318 in reported general payments places this provider in the 85th percentile of 31 vascular surgery providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 52 | $354 |
| Cilostazol | 29 | $253 |
| Pentoxifylline | 11 | $250 |
| ClopidogrelClopidogrel Bisulfate | 15 | $116 |
| Diazepam | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Ogden
- Brian AdamsOgden$14K
- Faheem AkhtarOgden$5K
- Evan BrownieMurray$206K
- Harrison LazarusWest Jordan$100K
- Craig SelzmanSalt Lake City$11K
- Douglas WirthlinMurray$9K
- Thomas SerenaSalt Lake City$8K
- Robert SmilanichProvo$6K
- Holly RyanSalt Lake City$5K
- Benjamin BrookeSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.